Coronavirus vaccine hopes rise as Oxford scientists reveal jab may offer 'double protection' against killer bug

A VACCINE developed by Oxford University scientists may offer a “double defence” against Covid-19, it has been reported.

Phase one of the human trials into the potentially-life saving jab have shown that it generates an immune response against the killer coronavirus.

⚠️ Read our coronavirus live blog for the latest news & updates

A senior source told the Telegraph that blood samples taken from UK volunteers showed the vaccine caused the body to produce both antibodies and “killer T-cells”.

Another source said the presence of both has been described as a “double defence” against the respiratory disease.

T-cells, known as "memory" cells, are made in response to an infection and, unlike antibodies, remain long afterwards.

While the results are “extremely promising”, they did not yet provide the vaccine would provide long-lasting immunity to the virus.

They said: “I can tell you that we now know the Oxford vaccine covers both bases – it produces both a T cell and an antibody response.


“It’s the combination of these two that will hopefully keep people safe.

“So far, so good. It’s an important moment. But we still have a long way to go.”

The full findings will be published in the Lancet medical journal on July 20.

The Oxford team previously said they are "80 per cent" confident they will have a working jab by September.


Meanwhile, hopes of a potential coronavirus vaccine being developed by US pharmaceutical firm Moderna also received a boost yesterday.

Experts yesterday said that their jab produced an immune response in 45 healthy volunteers in an ongoing early-stage study.

Writing in the New England Journal of Medicine (NEJM), researchers said volunteers who got two doses of the vaccine had high levels of antibodies which exceeded those seen in patients who have recovered from Covid.

Both experimental vaccines work by tricking the body into believing it has been infected with the virus to provoke an immune response that can then attack it.



A source on the Oxford team told ITV News: "An important point to keep in mind is that there are two dimensions to the immune response: antibodies and T-cells. 

"Everybody is focused on antibodies but there is a growing body of evidence suggesting that the T-cells response is important in the defence against coronavirus."


Oxford University researchers have partnered with drugs giant AstraZeneca, based in Cambridge, to mass produce it.

But researchers have found it difficult to recruit enough people to test it as coronavirus cases in the UK had fallen substantially after the end of March when the country was put in lockdown.

So they've been forced to new test subjects in Brazil and South Africa, where there has been a spike in new infections.

In his blog, ITV's political editor Robert Peston said: "Apparently the vaccine is generating the kind of antibody and T-cell (killer cell) response that the researchers would hope to see."

The Oxford team have yet to report Phase one results, which would show whether it is safe and whether or not it induces an immune response.

A spokeswoman for Oxford University today said the team was awaiting confirmation from a scientific journal of a publication date and time for the data, but gave no further details.


Earlier this month, the team said they were encouraged by the immune response they had seen in trials so far and were expecting to publish the data by the end of July.

More than 100 vaccines are being developed and tested around the world to try to stop the Covid-19 pandemic, which has killed hundreds of thousands.

AstraZeneca's experimental vaccine is probably the world's leading candidate and most advanced in terms of development, the World Health Organisation's chief scientist said in June.


Don't miss the latest news and figures – and essential advice for you and your family.

To receive The Sun’s Coronavirus newsletter in your inbox every tea time, sign up here.

To follow us on Facebook, simply ‘Like’ our Coronavirus page.

Get Britain’s best-selling newspaper delivered to your smartphone or tablet each day – find out more.

The company has signed agreements with governments around the globe to supply the vaccine should it be cleared for use.

It comes as researchers in the US reported that Moderna Inc's experimental vaccine showed it was safe and provoked immune responses in all 45 healthy volunteers in an ongoing early-stage study.

Moderna started its Phase 2 trial in May and expects to start a Phase 3 trial on July 27.

It said the vaccine triggered the immune response with mild side effects, including fatigue, chills, headache and muscle pain.

The company said it "remains on track to be able to deliver approximately 500 million doses per year, and possibly up to 1 billion doses per year, beginning in 2021."

Dr Anthony Fauci, the US government's top infectious disease expert, said: “No matter how you slice this, this is good news."

The vaccine was developed by Fauci’s colleagues at the National Institutes of Health alongside Moderna Inc.

Source: Read Full Article